Elicio Therapeutics (ELTX) Cash & Current Investments (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Cash & Current Investments data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 21.47% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (down 21.47% YoY), and the FY2025 full-year result was $18.6 million, down 1.24% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $14.9 million, down from $18.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $73.0 million in Q1 2022 and bottomed at $598000.0 in Q2 2022.
• The 5-year median for Cash & Current Investments is $16.5 million (2023), against an average of $17.7 million.
• The widest annual swing landed in 2022, when Cash & Current Investments tumbled 99.49%; it then soared 3525.75% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $7.8 million in 2022, then surged by 74.63% to $13.6 million in 2023, then surged by 38.04% to $18.8 million in 2024, then dropped by 1.24% to $18.6 million in 2025, then dropped by 19.47% to $14.9 million in 2026.
• The last three Cash & Current Investments figures came in at $14.9 million (Q1 2026), $18.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.

Peer Comparison